Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling compounded semaglutide by April 22, while outsourcing facilities have until May 22 to cease production and distribution.
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...
Weight loss drugs quickly became the go-to tactic for celebrities like Fat Joe, Kathy Bates, Macy Gray, Kelly Clarkson, Rebel ...
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...
Struggling with Ozempic? A registered dietitian reveals the 8 best foods to eat and 4 to avoid, plus expert tips on meal ...
Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...
Elon Musk wants to cut funding for scientific research, but the weight loss drugs he promoted also came from government funded basic science.
Hosted on MSN12h
Copycat Ozempic makers brace for crackdownMakers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback